Sugi Predict

Sugi Predict / Targets / NANS

NANS

N-acetylneuraminate-9-phosphate synthase · Q9NR45 · NANS on Sugi Atlas →

0 patent compounds predicted against NANS, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to NANS by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs) PHASE4COMPLETED
Efficacy Confirmation Study of NPC-09 PHASE3COMPLETED
Acelarin First Line Randomised Pancreatic Study PHASE2/PHASE3SUSPENDED
Multi-Center Study of ManNAc for GNE Myopathy PHASE2ACTIVE_NOT_RECRUITING
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy PHASE1COMPLETED
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases PHASE1COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
Sialic Acid Supplementation in N-Acetylneuraminic Acid Synthase (NANS) Deficiency nanCOMPLETED
The Natural History of Sialidosis Type I nanRECRUITING
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) nanWITHDRAWN
Evaluation of Blood Protein O-GlcNAcylation Levels in Children nanRECRUITING
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism nanNOT_YET_RECRUITING
Registry Gangliosidoses nanUNKNOWN
Evaluation of Blood and Cardiac Protein O-GlcNAcylation Levels in Cardiac Surgery in Children nanRECRUITING
Chest Wall Deformities in Children - Epidemiological Data nanCOMPLETED
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression nanCOMPLETED
Glycosylation in Patients With Galactosaemia nanCOMPLETED
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2) nanWITHDRAWN
BMN 110 US Expanded Access Program nanAPPROVED_FOR_MARKETING
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside nanUNKNOWN
Mucin Glycosylating Enzymes in Head and Neck Cancers nanUNKNOWN
Genome Environment Microbiome and Metabolome in Autism Study nanCOMPLETED
Biomarker for Sanfilippo Type A-B-C-D Disease (BioSanfilippo) nanWITHDRAWN
The Natural History of Alpha-Mannosidosis nanCOMPLETED
A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases nanCOMPLETED
Efficacy of a Rinse Containing Sea Salt and Lysozyme on Biofilm and Gingival Health nanCOMPLETED
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation nanCOMPLETED
Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in Mucopolysaccharidosis nanCOMPLETED
Using Next-generation Sequencing in the Diagnosis of Epilepsy and/or Intellectual Disability in a Pediatric Cohorte nanCOMPLETED
Genetic Studies of Lysosomal Storage Disorders nanENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a NANS binder may also engage these)

ProteinNameSimilarity
Q99J77 — 0.996 Q99J77 →
Q5E317 — 0.979 Q5E317 →
Q9VG74 — 0.979 Q9VG74 →
Q8A0V3 — 0.978 Q8A0V3 →
P57876 — 0.977 P57876 →
B7K7E4 — 0.977 B7K7E4 →
Q5WXA7 — 0.976 Q5WXA7 →
A4YED8 — 0.976 A4YED8 →
Q1D7A6 — 0.976 Q1D7A6 →
Q8RHX2 — 0.976 Q8RHX2 →
P13228 — 0.976 P13228 →
B0KSB8 — 0.976 B0KSB8 →
P35915 — 0.975 P35915 →
Q88MG0 — 0.975 Q88MG0 →
Q1I5W1 — 0.975 Q1I5W1 →
Q81II0 — 0.975 Q81II0 →
Q0P3Z2 — 0.975 Q0P3Z2 →
Q5F6P1 — 0.975 Q5F6P1 →
B8DM91 — 0.975 B8DM91 →
B3DF93 — 0.975 B3DF93 →
Q39W61 — 0.975 Q39W61 →
P61655 — 0.975 P61655 →
Q6HP28 — 0.974 Q6HP28 →
Q8RCF9 — 0.974 Q8RCF9 →
P57831 — 0.974 P57831 →
Q7N1X8 — 0.974 Q7N1X8 →
A4J541 — 0.974 A4J541 →
A8F7Z9 — 0.974 A8F7Z9 →
Q5ZWA3 — 0.974 Q5ZWA3 →
B4SR83 — 0.974 B4SR83 →